BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

XL281: Interim Phase I data

In an ongoing, open-label, dose-escalation, U.S. Phase I trial in 29 patients with cancer, once-daily oral XL281 resulted in 1 partial response and 12 patients with stable disease...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >